BioNTech SE (NASDAQ:BNTX) Short Interest Update

BioNTech SE (NASDAQ:BNTX - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 2,550,000 shares, a growth of 9.4% from the December 31st total of 2,330,000 shares. Based on an average daily volume of 806,600 shares, the days-to-cover ratio is presently 3.2 days.

BioNTech Price Performance

Shares of BioNTech stock traded up $5.42 during trading on Wednesday, hitting $122.56. 598,572 shares of the company were exchanged, compared to its average volume of 755,419. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a market capitalization of $29.38 billion, a price-to-earnings ratio of -58.43 and a beta of 0.17. The firm has a 50 day moving average price of $117.30 and a 200 day moving average price of $107.79.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 EPS. On average, equities analysts expect that BioNTech will post -3.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Planning Capital Management Corp raised its holdings in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after acquiring an additional 450 shares during the last quarter. Blue Trust Inc. raised its holdings in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after acquiring an additional 388 shares during the last quarter. GAMMA Investing LLC raised its holdings in BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company's stock valued at $74,000 after acquiring an additional 111 shares during the last quarter. AlphaCentric Advisors LLC acquired a new position in BioNTech in the 4th quarter valued at $168,000. Finally, SVB Wealth LLC acquired a new position in BioNTech in the 4th quarter valued at $204,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. The Goldman Sachs Group raised BioNTech from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. TD Cowen lowered their price objective on BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a report on Tuesday, November 5th. Truist Financial initiated coverage on BioNTech in a report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Finally, JPMorgan Chase & Co. lowered their price objective on BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a report on Tuesday, November 26th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $142.72.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.